3.67 0.00 (0.00%)
After hours: 7:30PM EST
|Bid||3.65 x 2200|
|Ask||3.67 x 1200|
|Day's Range||3.6000 - 3.8800|
|52 Week Range||1.5400 - 6.1900|
|Beta (3Y Monthly)||2.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 28, 2017 - Jul 31, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
NEW YORK, Jan. 09, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Bill & Melinda Gates Foundation invests ~$1M to develop novel technology for QS-21 - Grant to develop an alternative, novel plant cell-culture based method for QS-21 production LEXINGTON, Mass. , Jan. ...
HENDERSON NV / ACCESSWIRE / December 21, 2018 / Deals like the partnership between Gilead and Agenus are making the biotech industry red hot. Here are some biotech companies to look into. We are highlighting: ...
CORAL GABLES, FL / ACCESSWIRE / December 20, 2018 / The biotech industry has shown tremendous growth over the course of the last several months, as medical experts and professionals have sought to test ...
Shares of Agenus Inc. shot up 60% in premarket trade Thursday after the company announced it was partnering with Gilead Sciences Inc. to develop up to five immuno-oncology therapies. Under the deal, Agenus will receive $150 million upon closing, including a $120 million upfront cash payment and $30 million in equities. Agenus will also receive up to about $1.7 billion in potential future fees and milestones. Gilead, whose shares ticked up 0.3% in premarket trade after the announcement, will receive exclusive rights to one of Agenus' investigational therapies and options to license two others. Gilead will also have the right of first negotiation for two additional undisclosed pre-clinical programs. Shares of Agenus have fallen 38% in the year to date, while shares of Gilead have fallen 10%. The S&P 500 has fallen 6% in the year to date.
Gilead Sciences Inc has inked a collaboration agreement with Agenus Inc for the development and marketing of up to five novel immuno-oncology therapies. Agenus will get an upfront cash payment of $120 ...
Gilead Sciences, Inc. (GILD) and Agenus Inc. (AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel immuno-oncology therapies. Under the terms of the agreement, Agenus will receive $150 million upon closing, which includes a $120 million upfront cash payment and a $30 million equity investment. Gilead will receive worldwide exclusive rights to AGEN1423, which has an estimated IND filing by year-end 2018.
FOSTER CITY, Calif. and LEXINGTON, Mass., Dec. 20, 2018 /PRNewswire/ -- Gilead Sciences, Inc. (GILD) and Agenus Inc. (AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel immuno-oncology therapies. Under the terms of the agreement, Agenus will receive $150 million upon closing, which includes a $120 million upfront cash payment and a $30 million equity investment. The agreement also includes approximately $1.7 billion in potential future fees and milestones. Gilead will receive worldwide exclusive rights to AGEN1423, which has an estimated IND filing by year-end 2018.
NEW YORK, NY / ACCESSWIRE / December 17, 2018 / U.S. markets slumped on Friday as bank shares dragged equities lower amidst concerns about global economic slowdown after China’s industrial and sales growth ...
Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that it has appointed Evan Ballantyne as its Chief Financial Officer (CFO). Mr. Ballantyne is an experienced financial and strategic leader in the biotech, medical device and information services industries with a proven track record of building and strengthening a company’s financial position during his career of more than 25 years. David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed, commented, “Over the course of his career, Evan has played key roles in successfully leading companies in the full range of strategic options in financing including private equity and public offerings.
LEXINGTON, Mass. , Nov. 13, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies 1 , ...